**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

| | | |
|---|---|---|
| In re PATENT APPLICATION of | * | |
| | * | |
| ANDERSON et al. | * | Group Art Unit: Unassigned |
| | * | |
| Application Serial No. (Unassigned) | * | Examiner: Unassigned |
| | * | |
| Filed: July 25, 2001 | * | |

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

* * * *

**PRELIMINARY AMENDMENT**

Hon. Commissioner of Patents
Washington, DC 20231

Sir:

Prior to examination, kindly amend the claims as follows.

IN THE CLAIMS

Please cancel all of original claims 1-20 and enter the following new claims 21 to 69:

21. A chimeric anti-CD20 antibody having a variable light chain comprising the amino acid sequence encoded by the nucleic acid sequence in SEQ ID NO:6 and a variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.

22. An anti-CD20 variable light chain encoded by the nucleic acid sequence in SEQ ID NO:6.

23. An anti-CD20 variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.

24. A chimeric anti-CD20 antibody having a variable light chain encoded by the nucleic acid sequence in SEQ ID NO:6.

25. A chimeric anti-CD20 antibody having a variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.

26. The chimeric anti-CD20 antibody of Claim 21 which is an IgG1.

27. The chimeric anti-CD20 antibody of Claim 24 which is an IgG1.

28. The chimeric anti-CD20 antibody of Claim 25 which is an IgG1.

29. The chimeric anti-CD20 antibody of Claim 21 which comprises a radiolabel.

30. The chimeric anti-CD20 antibody of Claim 29 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

31. The chimeric anti-CD20 antibody of Claim 21 wherein said radiolabel is attached to the antibody via a chelate.

32. The chimeric anti-CD20 antibody of the Claim 31 wherein the chelate is MX-DTPA.

33. The chimeric anti-CD20 antibody of Claim 24 which comprises a radiolabel.

34. The chimeric anti-CD20 antibody of Claim 24 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

35. The chimeric anti-CD20 antibody of Claim 24 wherein said radiolabel is attached to the antibody via a chelate.

36. The chimeric anti-CD20 antibody of the Claim 24 wherein the chelate is MX-DTPA.

37. The chimeric anti-CD20 antibody of Claim 25 which comprises a radiolabel.

38. The chimeric anti-CD20 antibody of Claim 25 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (131) and iodine (131).

39. The chimeric anti-CD20 antibody of Claim 25 wherein said radiolabel is attached to the antibody via a chelate.

40. The chimeric anti-CD20 antibody of the Claim 25 wherein the chelate is MX-DTPA.

41. A pharmaceutical composition comprising a chimeric anti-CD20 antibody according to Claim 21 and a pharmaceutically acceptable carrier.

42. An imaging composition comprising a chimeric anti-CD20 antibody according to Claim 21 and an acceptable carrier.

43. The pharmaceutical composition of Claim 41 which comprises a radiolabel.

44. The imaging composition of Claim 42 which comprises a radiolabel.

45. The pharmaceutical composition of Claim 43 wherein said radiolabel is yttrium (90) or iodine (131).

46. The imaging composition of Claim 44 wherein said radiolabel is indium (111).

47. The pharmaceutical composition of Claim 41 which is suitable for parenteral administration.

48. The pharmaceutical composition of Claim 47 wherein parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous.

49. The imaging composition of Claim 42 which is suitable for parenteral administration.

50. The imaging composition of Claim 49 wherein parenteral administration is selected from the group consisting of subcutaneous, intravenous, intramuscular, vaginal, intraperitoneal and subcutaneous.

51. The pharmaceutical composition of Claim 41 which delivers an effective dosage ranging from about 0.01 to 30 mg/kg body weight.

52. The pharmaceutical composition of Claim 51 wherein said dosage ranges from about 0.01 to about 25 mg/kg body weight.

53. The pharmaceutical composition of Claim 51 wherein said dosage ranges from about 0.4 mg to about 20.0 mg/kg body weight.

54. The imaging composition of Claim 42 which delivers a dosage of radiation ranging from about 1 to 10 mCi.

55. The imaging composition of Claim 54 wherein the radiolabel is indium (111).

56. The imaging composition of Claim 55 wherein the dosage of radiation is about 5 mCi.

57. The pharmaceutical composition of Claim 43 which is non-myeloablative.

58. An anti-CD20 antibody comprising a variable light chain encoded by the nucleic acid sequence in SEQ ID NO:6.

59. The anti-CD20 antibody of Claim 58 wherein said antibody is murine.

60. The anti-CD20 antibody of Claim 59 further comprising a radiolabel.

61. The anti-CD20 antibody of Claim 60 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (111), and iodine (131).

62. The anti-CD20 antibody of Claim 61 wherein said radiolabel is yttrium (90).

63. An anti-CD20 antibody comprising a variable heavy chain encoded by the nucleic acid sequence in SEQ ID NO:9.

64. The anti-CD20 antibody of Claim 63 wherein said antibody is murine.

65. The anti-CD20 antibody of Claim 63 further comprising a radiolabel.

66. The anti-CD20 antibody of Claim 64 wherein said radiolabel is selected from the group consisting of yttrium (90), indium (111), and iodine (131).

67. The anti-CD20 antibody of Claim 65 wherein said radiolabel is yttrium (90).

**REMARKS**

The newly added claims find support from the as-filed specification as follows:

All of claims find explicit support at pages 11-24 of the specification and the Sequence Listing submitted with the parent application, now U.S. Patent 5,736,137. The Examiner is respectfully requested to enter this Sequence Listing in this application.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: _____
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000
(703) 905-2500 Facsimile

Date: July 25, 2001